Enhancing Lung Cancer Surgical Quality: Insights from the American College of Surgeons’ National Quality Improvement Collaborative

Highlights

• The Lung NODES National Quality Improvement Collaborative significantly improved compliance with the American College of Surgeons’ Operative Standard 5.8 for lymph node sampling during lung cancer surgery, increasing median hospital compliance from 67.8% to 90.5%.
• Multimodal prehabilitation and rigorous perioperative risk stratification tools enhance patient selection and postoperative outcomes in lung cancer surgery.
• Centralized quality assurance programs in stereotactic body radiation therapy (SBRT) ensure treatment protocol adherence, optimizing local control and safety in operable and inoperable lung cancer patients.
• Real-world evidence supports external beam radiation therapy (EBRT) superiority over other interventions for complicated malignant central airway obstruction, signifying the expanding role of multidisciplinary strategies in thoracic oncology.

Background

Lung cancer remains the leading cause of cancer-related mortality worldwide. Surgical resection for early-stage non-small cell lung cancer (NSCLC) offers the best chance at cure, contingent upon accurate staging and optimal operative technique. Adequate hilar and mediastinal lymph node assessment is critical for accurate staging, guiding adjuvant therapy, and improving survival outcomes. The American College of Surgeons (ACS) Commission on Cancer (CoC) implemented Operative Standard 5.8, recommending sampling of at least three mediastinal and one hilar nodal stations during curative lung resection. However, achieving high compliance with this standard across diverse hospital settings has been challenging, necessitating coordinated quality improvement initiatives. Concurrently, advances in perioperative risk assessment, prehabilitation, and radiation therapy techniques are reshaping comprehensive lung cancer care pathways.

Key Content

Quality Improvement in Surgical Lymph Node Sampling: The Lung NODES Collaborative

The Lung NODES National QI Collaborative, initiated by the ACS CoC, enrolled 354 accredited surgical programs across the United States between March and December 2024 to address compliance gaps with Standard 5.8. Participating centers engaged in guided root cause analyses, educational sessions, and peer-led strategy development targeting lymph node assessment practices. The initiative yielded a significant increase in hospitals achieving ≥80% compliance—from 40.7% at baseline to 67.2% post-intervention. Median hospital compliance rose markedly from 67.8% (IQR 42.9%-90%) to 90.5% (IQR 70%-100%), with community hospitals demonstrating the largest absolute improvement (37.1%). Adjusted multilevel logistic regression confirmed a 2.5-fold increased odds of compliant lymph node assessment post-participation. These findings underscore the effectiveness of coordinated national QI efforts in standardizing surgical quality irrespective of hospital type or baseline performance.

Integrating Perioperative Risk Stratification and Prehabilitation

Optimal patient selection and surgical outcomes depend on robust perioperative risk assessment. Comparative analyses of tools such as the ACS Surgical Risk Calculator (ACS-SRC), Revised Risk Analysis Index (RAI-rev), and Modified Frailty Index (5-mFI) demonstrated superior predictive discrimination of the ACS-SRC for 30-day morbidity, mortality, and readmission among lung cancer resection patients (AUC for mortality 0.74). Risk calculators enhance shared decision-making and perioperative planning.

Parallel to risk stratification, multimodal prehabilitation—including physical conditioning, nutritional optimization, and respiratory therapy—has demonstrated significant reductions in postoperative complications and readmission rates. A propensity score-matched retrospective study reported a decrease in overall complication rates from 65.3% to 46.3% and major complications from 27.9% to 13.6%, improved Comprehensive Complication Index scores, and lowered ICU admissions in prehabilitated patients. These interventions directly address frailty and limited functional reserve prevalent in the lung cancer surgical population.

Advances in Radiation Therapy Quality Assurance and Management of Complex Thoracic Conditions

Centralized quality assurance in stereotactic body radiotherapy (SBRT) for early-stage operable and inoperable NSCLC has enhanced protocol adherence and safety profiles. The Veterans Affairs Cooperative Studies Program Study Number 2005 demonstrated meticulous contouring, dose prescription, and target coverage with minimal protocol deviations across 100 patients. Such centralized frameworks prevent under- or overtreatment, critical for patient safety and treatment efficacy.

For cases of malignant central airway obstruction (MCAO), real-world comparative data advocate for external beam radiation therapy (EBRT) as a first-line treatment over stenting, bronchoscopic debulking, or combination therapies. Large matched cohort analyses reveal EBRT-associated survival benefits, particularly early mortality reduction, and recommend procedural interventions reserved for urgent airway compromise. These findings highlight the evolving multidisciplinary approach incorporating quality-assured radiation modalities and nuanced surgical care.

Expert Commentary

The improvement in lymph node staging compliance achieved by the Lung NODES collaborative validates the utility of structured quality improvement initiatives within national surgical networks. The collaborative’s success demonstrates how shared best practices, continuous education, and peer support foster sustainable behavioral and process changes at institutional levels. Importantly, the largest gains seen in community hospitals reflect the bridging of care disparities.

Translationally, accurate mediastinal staging enables tailored adjuvant systemic therapies, now increasingly personalized by molecular profiling, underscoring staging’s prognostic and therapeutic implications. The integration of standardized staging with robust perioperative assessment and patient optimization strategies forms a comprehensive surgical quality framework.

Despite advances, challenges remain in uniformly implementing best practices nationwide, especially with heterogeneous hospital resources and patient populations. Future efforts should address barriers such as surgical training variability, intraoperative lymph node sampling techniques, and real-time operative feedback mechanisms.

Moreover, ongoing integration of quality assurance in radiation oncology trials complements surgical quality improvements, ensuring multimodal lung cancer care excellence. The LungTech and VALOR trials exemplify the importance of prospective monitoring to maintain treatment fidelity and patient safety in SBRT, with implications for adjuvant and non-surgical candidate management.

The incorporation of advanced risk calculators into preoperative planning enhances perioperative safety and resource utilization. Further research should explore dynamic integration of frailty and inflammatory biomarkers identified in emerging studies to predict postoperative pain and recovery trajectories effectively.

Conclusion

The American College of Surgeons’ Lung NODES National Quality Improvement Collaborative represents a landmark effort in elevating lung cancer surgical staging quality at scale. Significant improvements in compliance with Operative Standard 5.8 demonstrate that coordinated, data-driven quality initiatives can overcome institutional variability and foster implementation of evidence-based surgical standards. Coupled with enhanced perioperative risk stratification, prehabilitation, and rigorous radiation therapy quality assurance, these advances collectively contribute to comprehensive lung cancer care improvements. Continued multidisciplinary collaboration, rigorous quality assessment, and adoption of emerging biomarkers will be pivotal in further optimizing outcomes for lung cancer patients.

References

• Chan K, Reilly EM, Jacobs RC, et al. An American College of Surgeons National Quality Improvement Collaborative to Enhance Lung Cancer Surgical Quality. JAMA Surg. 2026;161(6):609-617. PMID: 41984453.
• Camara-Clayette V, Mamberti A, Tanguy R-A, et al. Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026;125(1):78-85. PMID: 40714135.
• McCarthy M, Shah H, et al. Real-world faceoff: EBRT vs interventions for malignant central airway obstruction. Ann Am Thorac Soc. 2026;23(4):614-620. PMID: 41915561.
• Pascoe L, et al. A Potential Link Between Preoperative Inflammation Biomarkers and Acute Postoperative Pain Following VATS. Clin J Pain. 2026;42(4):e1355. PMID: 41472465.
• López-Pastor A, et al. The effect of multimodal prehabilitation on postoperative outcomes in lung cancer surgery. J Thorac Cardiovasc Surg. 2025;169(6):1631-1644.e2. PMID: 40043941.
• Farrell TJ, et al. Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). Pract Radiat Oncol. 2025;15(1):e29-e39. PMID: 39233006.
• Brunelli A, et al. Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection. J Surg Oncol. 2024;130(8):1532-1538. PMID: 39387593.
• Boeck L, et al. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results. J Thorac Oncol. 2024;19(9):1297-1309. PMID: 38788924.